P52298

PR
Gene name
NCBP2 (CBP20, PIG55)
Protein name
Nuclear cap-binding protein subunit 2
Names
20 kDa nuclear cap-binding protein, Cell proliferation-inducing gene 55 protein, NCBP 20 kDa subunit, CBP20, NCBP-interacting protein 1, NIP1
Species
Homo sapiens (Human)
KEGG Pathway
hsa:22916
EC number
Protein Class

Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

1-56 (Predicted disordered autoinhibitory region) PR

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

References

Autoinhibited structure

Activated structure

16 structures for P52298

Entry ID Method Resolution Chain Position Source
1H2T X-ray 215 A Z 1-156 PDB
1H2U X-ray 240 A X/Y 1-156 PDB
1H2V X-ray 200 A Z 1-156 PDB
1H6K X-ray 200 A X/Y/Z 22-120 PDB
1N52 X-ray 211 A B 1-156 PDB
1N54 X-ray 272 A B 1-156 PDB
3FEX X-ray 355 A B 1-156 PDB
3FEY X-ray 220 A B 1-156 PDB
5OO6 X-ray 280 A B/E/H/K/N/Q/T/W 1-156 PDB
5OOB X-ray 279 A B/D/G/J 1-156 PDB
6D0Y X-ray 268 A A 1-156 PDB
7ABG EM 780 A A1 1-156 PDB
8BY6 EM 319 A B 1-156 PDB
8PMP EM 343 A B 1-156 PDB
8PNT EM 346 A B 1-156 PDB
AF-P52298-F1 Predicted AlphaFoldDB

73 variants for P52298

Variant ID(s) Position Change Description Diseaes Association Provenance
rs1186248524
CA355647946
 2 S>W No ClinGen
gnomAD
CA2783517
rs774052722
 3 G>V No ClinGen
ExAC
gnomAD
CA2783515
rs763153091
 4 G>S No ClinGen
ExAC
gnomAD
rs770008541
CA2783513
 5 L>F No ClinGen
ExAC
gnomAD
CA2783512
rs574066503
 8 A>V No ClinGen
1000Genomes
ExAC
gnomAD
rs777314085
CA90931236
 9 L>M No ClinGen
ExAC
TOPMed
gnomAD
rs1157400152
CA355647903
 10 R>H No ClinGen
TOPMed
rs148063563
CA355647894
 11 S>R No ClinGen
ESP
TOPMed
TCGA novel 12 D>N Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
CA355647883
rs1446928197
 13 S>P No ClinGen
gnomAD
rs1330749831
CA355647868
 15 V>L No ClinGen
gnomAD
CA2783457
rs757041577
 29 N>S No ClinGen
ExAC
TOPMed
gnomAD
rs1257370613
CA355647409
 33 E>K No ClinGen
TOPMed
rs1267352112
CA355647400
 34 K>E No ClinGen
gnomAD
CA2783455
rs764326037
 35 L>* No ClinGen
ExAC
TOPMed
gnomAD
CA355647357
rs1560169934
 40 C>R No ClinGen
Ensembl
CA2783453
rs760696628
 41 T>M Variant assessed as Somatic; 4.63e-05 impact. [NCI-TCGA] No ClinGen
ExAC
NCI-TCGA
gnomAD
CA355647329
rs1412208746
 44 V>I No ClinGen
gnomAD
CA2783449
rs766744099
 52 T>A Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
ExAC
NCI-TCGA
gnomAD
CA355647271
rs1367552866
 52 T>I No ClinGen
gnomAD
CA355647258
rs1577863833
 54 E>G No ClinGen
Ensembl
TCGA novel 54 E>K Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
TCGA novel 57 Y>C Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs1457627776
CA355647229
 58 E>K No ClinGen
gnomAD
CA2783447
rs776180044
 60 F>L No ClinGen
ExAC
gnomAD
CA355647207
rs1401681235
 61 S>N No ClinGen
TOPMed
TCGA novel 63 S>R Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs768397521
CA2783446
 64 G>D No ClinGen
ExAC
gnomAD
CA355647079
rs1219415377
 78 K>R No ClinGen
TOPMed
CA355647070
rs1210059459
 79 T>I No ClinGen
gnomAD
rs1208737397
CA355647021
 86 V>A No ClinGen
TOPMed
CA2783441
rs771482269
 87 E>A No ClinGen
ExAC
gnomAD
CA2783401
rs765642228
 87 E>D No ClinGen
ExAC
TOPMed
rs1480644212
CA2783397
 91 R>H No ClinGen
TOPMed
rs538938257
CA2783395
 92 A>T No ClinGen
ExAC
TOPMed
gnomAD
CA355646967
rs1170003941
 93 D>H Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
NCI-TCGA
gnomAD
CA2783393
rs759229687
 94 A>V No ClinGen
ExAC
TOPMed
gnomAD
CA355646951
rs1311835609
 95 E>G No ClinGen
gnomAD
rs763014780
CA2783390
 97 A>T No ClinGen
ExAC
gnomAD
rs1187455890
CA355646930
 98 M>T No ClinGen
gnomAD
CA2783388
rs769652626
COSM209419
 99 R>Q large_intestine [Cosmic] No ClinGen
cosmic curated
ExAC
gnomAD
COSM583015
CA355646924
rs772956368
 99 R>W lung Variant assessed as Somatic; impact. [Cosmic, NCI-TCGA] No ClinGen
cosmic curated
ExAC
NCI-TCGA
TOPMed
gnomAD
CA355646912
rs1205882210
 101 I>V No ClinGen
gnomAD
rs1393864695
CA355646896
 103 G>W No ClinGen
TOPMed
CA2783386
rs780934944
 104 T>M Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
ExAC
NCI-TCGA
gnomAD
rs1299820445
CA355646884
 105 R>H No ClinGen
TOPMed
CA355646863
rs1284630736
 108 D>V No ClinGen
gnomAD
CA355646858
rs1447181833
 109 R>* No ClinGen
gnomAD
CA355646815
rs1309778781
 112 R>H No ClinGen
gnomAD
rs1560168884
CA355646801
 113 T>I No ClinGen
Ensembl
rs779236116
CA2783380
 117 A>T No ClinGen
ExAC
gnomAD
CA2783379
rs757669361
 117 A>V No ClinGen
ExAC
TOPMed
gnomAD
TCGA novel 118 G>V Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
CA2783378
rs754192964
 119 F>V No ClinGen
ExAC
gnomAD
rs1436504113
CA355646686
 121 E>D No ClinGen
TOPMed
gnomAD
TCGA novel 122 G>A Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs754735060
CA2783376
 123 R>G No ClinGen
ExAC
gnomAD
CA355646639
rs1387715066
 125 Y>H No ClinGen
gnomAD
rs762320814
CA2783373
 127 R>C Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
ExAC
NCI-TCGA
gnomAD
rs1003820610
CA90926833
 129 R>* No ClinGen
Ensembl
rs1465796391
CA355646589
 129 R>Q No ClinGen
gnomAD
CA90926825
rs140528319
 131 G>W No ClinGen
ESP
gnomAD
rs1433793609
CA355646419
 139 R>Q No ClinGen
gnomAD
rs761725822
CA2783348
 141 D>E No ClinGen
ExAC
gnomAD
rs764792682
CA2783349
 141 D>G No ClinGen
ExAC
gnomAD
rs776488343
CA2783347
 142 Y>D No ClinGen
ExAC
gnomAD
CA355646401
rs776488343
 142 Y>H No ClinGen
ExAC
gnomAD
CA355646375
rs1577860476
 146 R>G No ClinGen
Ensembl
CA2783344
rs775717046
COSM3847166
 147 G>A Variant assessed as Somatic; 0.0 impact. breast [NCI-TCGA, Cosmic] No ClinGen
cosmic curated
ExAC
NCI-TCGA
gnomAD
rs1302140345
CA355646339
 151 K>R No ClinGen
gnomAD
rs746078417
CA2783342
 154 Q>* No ClinGen
ExAC
TOPMed
gnomAD
rs774350997
CA2783341
 156 Q>R No ClinGen
ExAC
gnomAD
rs1234160227
CA355646301
 157 Q>R No ClinGen
TOPMed

No associated diseases with P52298

2 regional properties for P52298

Type Name Position InterPro Accession
domain RNA recognition motif domain 40 - 118 IPR000504
domain NCBP2, RNA recognition motif 42 - 119 IPR034148

Functions

Description
EC Number
Subcellular Localization
  • Nucleus
  • Cytoplasm
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

7 GO annotations of cellular component

Name Definition
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
cytosol The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
mRNA cap binding complex Any protein complex that binds to an mRNA cap at any time in the lifetime of the mRNA.
nuclear cap binding complex A conserved heterodimeric protein complex that binds to the 5' terminal cap structure m7G(5')ppp(5')N of nascent eukaryotic RNA polymerase II transcripts such as pre-mRNA and U snRNA. The consists of proteins known as CBP20 and CBP80, binds to cap structures in the nucleus, and is involved in pre-mRNA splicing, 3'-end formation, and RNA nuclear export.
nucleoplasm That part of the nuclear content other than the chromosomes or the nucleolus.
nucleus A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.
RNA cap binding complex Any protein complex that binds to a specialized RNA cap structure at any time in the lifetime of the RNA.

6 GO annotations of molecular function

Name Definition
DNA binding Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid).
mRNA binding Binding to messenger RNA (mRNA), an intermediate molecule between DNA and protein. mRNA includes UTR and coding sequences, but does not contain introns.
RNA 7-methylguanosine cap binding Binding to a 7-methylguanosine group added cotranscriptionally to the 5' end of RNA molecules transcribed by polymerase II.
RNA binding Binding to an RNA molecule or a portion thereof.
RNA cap binding Binding to a 7-methylguanosine (m7G) group or derivative located at the 5' end of an RNA molecule.
snRNA binding Binding to a small nuclear RNA (snRNA).

19 GO annotations of biological process

Name Definition
alternative mRNA splicing, via spliceosome The process of generating multiple mRNA molecules from a given set of exons by differential use of exons from the primary transcript(s) to form multiple mature mRNAs that vary in their exon composition.
cap-dependent translational initiation The process where the cap structure, composed of a 7- methylguanosine (m7G) group and associated cap-binding proteins, located at the 5' end of an mRNA molecule, which serves as a molecular tag that marks the spot where the 40S ribosomal subunit, is recruited and will then scan in a 5' to 3' direction until an AUG codon is encountered in an appropriate sequence context to initiate mRNA translation.
histone mRNA metabolic process The chemical reactions and pathways involving an mRNA encoding a histone.
miRNA-mediated gene silencing A post-transcriptional gene silencing pathway in which regulatory microRNAs (miRNAs) elicit silencing of specific target genes. miRNAs are endogenous 21-24 nucleotide small RNAs processed from stem-loop RNA precursors (pre-miRNAs). Once incorporated into a RNA-induced silencing complex (RISC), miRNAs can downregulate gene expression by either of two posttranscriptional mechanisms: endonucleolytic cleavage of the RNA (often mRNA) or mRNA translational repression, usually accompanied by poly-A tail shortening and subsequent degradation of the mRNA. miRNAs are present in all the animals and in plants, whereas siRNAs are present in lower animals and in plants.
mRNA 3'-end processing Any process involved in forming the mature 3' end of an mRNA molecule.
mRNA cis splicing, via spliceosome The joining together, after removal of an intervening sequence composed of one or more introns, of two segments of the same RNA molecule via spliceosomal catalysis to produce an mRNA composed only of exon sequences that all came from the same primary transcript.
mRNA export from nucleus The directed movement of mRNA from the nucleus to the cytoplasm.
mRNA splicing, via spliceosome The joining together of exons from one or more primary transcripts of messenger RNA (mRNA) and the excision of intron sequences, via a spliceosomal mechanism, so that mRNA consisting only of the joined exons is produced.
mRNA transcription by RNA polymerase II The cellular synthesis of messenger RNA (mRNA) from a DNA template by RNA polymerase II, originating at an RNA polymerase II promoter.
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay The nonsense-mediated decay pathway for nuclear-transcribed mRNAs degrades mRNAs in which an amino-acid codon has changed to a nonsense codon; this prevents the translation of such mRNAs into truncated, and potentially harmful, proteins.
positive regulation of mRNA 3'-end processing Any process that activates or increases the frequency, rate or extent of mRNA 3'-end processing.
positive regulation of phosphorylation of RNA polymerase II C-terminal domain Any process that activates or increases the frequency, rate or extent of phosphorylation of RNA polymerase II C-terminal domain.
positive regulation of RNA export from nucleus Any process that activates or increases the frequency, rate or extent of directed movement of RNA from the nucleus into the cytoplasm.
positive regulation of transcription elongation by RNA polymerase II Any process that activates or increases the frequency, rate or extent of transcription elongation, the extension of an RNA molecule after transcription initiation and promoter clearance by the addition of ribonucleotides, catalyzed by RNA polymerase II.
pre-mRNA cleavage required for polyadenylation The targeted, endonucleolytic cleavage of a pre-mRNA, required for polyadenylation of the 3' end. This cleavage is directed by binding sites near the 3' end of the mRNA and leaves a 3' hydoxyl end which then becomes a target for adenylation.
primary miRNA processing A process involved in the conversion of a primary microRNA transcript into a pre-microRNA molecule.
regulation of translational initiation Any process that modulates the frequency, rate or extent of translational initiation.
RNA splicing The process of removing sections of the primary RNA transcript to remove sequences not present in the mature form of the RNA and joining the remaining sections to form the mature form of the RNA.
snRNA export from nucleus The directed movement of snRNA from the nucleus to the cytoplasm.

8 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q08920 CBC2 Nuclear cap-binding protein subunit 2 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) PR
Q5ZKR5 NCBP2 Nuclear cap-binding protein subunit 2 Gallus gallus (Chicken) PR
Q9CQ49 Ncbp2 Nuclear cap-binding protein subunit 2 Mus musculus (Mouse) PR
B1WC40 Ncbp2 Nuclear cap-binding protein subunit 2 Rattus norvegicus (Rat) PR
Q93594 ncbp-2 Nuclear cap-binding protein subunit 2 Caenorhabditis elegans PR
Q1HE01 Nuclear cap-binding protein subunit 2 Bombyx mori (Silk moth) PR
Q6DES0 ncbp2 Nuclear cap-binding protein subunit 2 Xenopus tropicalis (Western clawed frog) (Silurana tropicalis) PR
Q8JGR6 ncbp2 Nuclear cap-binding protein subunit 2 Danio rerio (Zebrafish) (Brachydanio rerio) PR
10 20 30 40 50 60
MSGGLLKALR SDSYVELSQY RDQHFRGDNE EQEKLLKKSC TLYVGNLSFY TTEEQIYELF
70 80 90 100 110 120
SKSGDIKKII MGLDKMKKTA CGFCFVEYYS RADAENAMRY INGTRLDDRI IRTDWDAGFK
130 140 150
EGRQYGRGRS GGQVRDEYRQ DYDAGRGGYG KLAQNQ